Quantitative analysis of cabozantinib in pharmaceutical dosage forms using green RP-HPTLC and green NP-HPTLC methods: A comparative evaluation

In this study, a novel antitumor drug cabozantinib (CZN) was estimated by a validated green reversed-phase high-performance thin-layer chromatography (RP-HPTLC) and normal-phase high-performance thin-layer chromatography (NP-HPTLC) techniques in the marketed tablets and capsules. The RP-HPTLC densitometry analysis of CZN was carried out using RP-18 silica gel 60 F254S HPTLC plates. Green acetone/water (85:15, v v-1) combination was applied as the mobile phase for a RP-HPTLC-densitometry. However, green NP-HPTLC analysis of CZN was conducted using NP-18 silica gel 60 F254S HPTLC plates. Green ethyl acetate/ethanol (97.5:2.5, v v-1) combination was applied for a green NP-HPLTC-densitometry. The detection of CZN was performed at lambda max = 247 nm for both of the techniques. The RP-HPTLC technique showed high sensitivity for the quantification of CZN in comparison to NP-HPTLC-densitometry. For a green RP-HPTLC-densitometry, the CZN content of marketed tablets and capsules were found to be 101.17% and 98.77%, respectively. However, for a green NP-HPTLC-densitometry, the CZN content of the marketed tablets and capsules were found to be 96.12% and 94.25%, respectively. Accordingly, the green RP-HPTLC technique was identified better than a green NPHPTLC technique. Hence, the RP-HPTLC-densitometry can be successfully used for the quantification of CZN in pharmaceutical dosage forms containing CZN as one of the constituents.

Automated summary

The novel antitumor drug cabozantinib was evaluated using validated green RP-HPTLC and NP-HPTLC techniques in marketed tablets and capsules. The RP-HPTLC demonstrated higher sensitivity for quantification of CZN compared to NP-HPTLC, making it a more suitable technique for analyzing pharmaceutical dosage forms containing CZN.